Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 24 May 2012
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final appraisal determination document
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): consultee and commentator comments on the ACD
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): comments on the ACD received from the public through the NICE website
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): additional evidence submitted by Roche
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group critique of additional evidence
This page was last updated: 08 May 2012